Presenting key role of excipients in continuous manufacturing at APV 2025 Basel

Wasserburg, Germany: – Pharmaceutical excipient industry leader MEGGLE will be a prominent presence as sponsor and co-presenter at the upcoming 6th Continuous Manufacturing (CM) Conference organized by industry body APV in Basel this month.

MEGGLE has become one of the APV Continuous Manufacturing Conference’s leading supporters, having attended every edition since the event was founded in 2019.

Speaking for IPEC Europe

The conferenced presentation will involve a collaboration between MEGGLE, BASF, and the International Pharmaceutical Excipients Council (IPEC), the global organization that promotes quality and safety in pharmaceutical excipients.

MEGGLE’s Global Application Manager Dr. Rebekka Spellerberg and Christian Becker of BASF SE will make successive presentations to the Formulation Development session on the first morning of the conference that together sum up IPEC Europe’s views on the regulatory aspects of Co-processed Excipients (CPE) and their application in continuous manufacturing (CM).

Excipients in CM

Dr. Spellerberg will focus on this latter aspect in her presentation: ‘Synergy in action: Industrial perspective of co-processed excipients by IPEC’. This will highlight the benefits of using co-processed excipients in the continuous manufacturing utilizing direct compression.

MEGGLE has become a leading force in advancing continuous manufacturing processes in pharma manufacturing by developing a range of lactose-based excipients specifically engineered to support continuous production processes in wet and dry granulation as well as direct compression. It has also developed a specific web-based landing page for CM-adapted excipients, with quick access from any device via QR code.

About MEGGLE Wasserburg

Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.

MEGGLE’s Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovation in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.

The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About APV Continuous Manufacturing Conference 2025

Based in Mainz, Germany, APV is an international pharma industry organization that focuses on pharmaceutical technology and industrial pharmacy, dedicated to “Making Science Work” through deepening understanding in scientific research and practical knowledge in areas such as development, manufacturing, analysis, and quality assurance.

APV organizes a series of events, including the annual Continuous Manufacturing conference that covers topics such as formulation development approaches, material characteristics, continuous coating, PAT and software systems. This has now become a must-attend networking event for Continuous Manufacturing professionals, including formulation & process developers, engineers, quality control managers, academia, and regulatory authorities.

The 6th CM Conference will be a two-day event opening April 8 at the Gehry Auditorium that forms the architectural centerpiece of the NOVARTIS Campus in Basel, Switzerland. The 2025 conference will feature keynote presentations on application of PAT process automation and significant progress by Novartis towards CM in production of large molecule drugs. The meeting will also include sessions on Formulation Development, the Semi-continuous approach, Continuous coating, Risk assessment and control strategies and Regulatory aspects.

The event is organized by APV with further information at: https://www.apv-mainz.de/en/events/seminars/details/seminar/7034.html

Resources

Click on MEGGLE Excipients: Cornerstones for reliable Continuous Manufacturing (CM) processes to learn more.